Lynk Pharmaceuticals Announces First Cohort of Psoriatic Patients Dosed with LNK01004
Lynk Pharmaceuticals, an innovative clinical stage company, announced that it has dosed the first cohort of psoriatic patients in a Phase Ib clinical trial of its innovative drug LNK01004. The trial was designed to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of LNK01004 ointment in Chinese patients with mild to moderate plaque psoriasis.
Psoriasis is an immune-mediated, chronic, relapsing, inflammatory skin disease characterized by scaly erythematous or plaque lesions that can be local or widely distributed. Patients often require lifelong treatment to control symptoms and prevent complications from occurring or developing, thereby maintaining their quality of life. LNK01004 ointment is a topical, skin-restricted soft pan JAK inhibitor intended for the treatment of psoriasis and other related conditions. The drug is mainly distributed in the skin tissues, but has minimal exposure in the blood system thereby avoiding potential safety issues caused by systemic immune suppression due to systemic exposure. As a representative third-generation JAK inhibitor, LNK01004 has the potential to be a first-in-class treatment.
Dr. Henry Wu, Chief Development Officer of Lynk Pharmaceuticals, said, “The completion of dosing the first cohort of patients with LNK01004 is an important milestone for the development of this compound. LNK01004 has already shown good efficacy and safety in preclinical animal studies. Its phase I trial in healthy subject was completed earlier this year, and the results showed good safety profile. We look forward to LNK01004’s good performance in patient trials.”
“As a third-generation JAK inhibitor, LNK01004 can effectively inhibit psoriasis-related cytokine-induced JAK/STAT signaling pathways in skin tissues by topical application. Additionally, LNK01004 has the advantage of extremely low exposure in the blood system to potentially avoid safety concerns due to systemic exposure,” said Dr. Zhao-Kui (ZK) Wan, founder & CEO of Lynk Pharmaceuticals.” Lynk is committed to develop safer and more efficacious JAK inhibitors. The differentiated products are our core competitive advantages. In addition to the highly selective JAK1 inhibitor LNK01001, we have also assembled a promising pipeline consisting of multiple third-generation, tissue-restricted soft pan JAK inhibitors in clinical trials including the GI-restricted LNK01003 for UC which is currently in Phase IIa. We sincerely look forward to bringing safer, more efficacious and innovative treatment options to patients.”
- Providence Therapeutics Announces Partnership with University Health Network (UHN) for mRNA Therapeutic Discovery and Development Read more
- Affini-T Therapeutics Appoints Industry Veteran Thaminda Ramanayake, M.S., MBA, as Chief Business Officer Read more
- Feinstein Institutes Bioelectronic Medicine Researchers Stimulate Vagus Nerve to Reduce Bleeding in Hemophilia Read more
- Kyverna Therapeutics Granted FDA Fast Track Designation for KYV-101 in Lupus Nephritis Read more
- Arcturus Therapeutics Receives U.S. FDA Fast Track Designation for ARCT-810, mRNA Therapeutic Candidate for Ornithine Transcarbamylase Deficiency Read more